Will Eylea K-biosimilar overcome evergreening in the U.S.?
By Hwang, Byung-woo | translator Kang, Shin-Kook
24.07.16 06:05:15
가나다라
0
Samsung Bioepis, first to receive approval in the US...stalled by the original company's patent lawsuit
US court granted preliminary injunction in June, prolongs patent issue
The expiration of the U.S. substance patent for the blockbuster biopharmaceutical Eylea (aflibercept) is expected to spark competition in the biosimilar market.
Samsung Bioepis, which preemptively received marketing authorization for an Eylea biosimilar, is stuck in a patent dispute with Regeneron, which owns the original Eylea. It is expected that other latecomers will also face a tough time entering the market depending on Regeneron’s patent response.
▲Pic of Eylea
Eylea is a treatment for eye diseases such as macular degeneration that binds to vascular endothelial growth factor (VEGF) and inhibits neovascularization. The drug generated global market sales of KRW 13 trillion. Of these, the U.S. mar
Hwang, Byung-woo(tuai@dailypharm.com)
If you want to see the full article, please JOIN US (click)